

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Health Technology Appraisal

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (Part-review of TA75 and TA106)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

	Proposed consultee:	Proposal made by:	Action taken:	Justification:
1.	<p>HCV Action</p> <p>Action on Hepatitis C no longer exists and there is a new, broad group of medical professionals with an interest in hepatitis C, including clinicians, GPs and nurses, called HCV Action that should be included. Its chair is Dr Stephan Ryder of Queen's Medical Centre, Nottingham – stephan.ryder@nuh.nhs.uk</p>	The Hepatitis C Trust	Action on Hepatitis C has been removed and HCV Action has been added.	

2.	Hepatitis C Trust Roche believe that the following organisation should be included as commentators: (Mr Charles Gore, charles@hepctrust.org.uk)	Roche	The Hepatitis C Trust are already on the matrix.	
----	--------------------------------------------------------------------------------------------------------------------------------------------------------------	-------	--------------------------------------------------	--

The following Consultees and Commentators made no comment:

- British Liver Nurses' Forum
- Royal College of Nursing
- Schering-Plough
- Department of Health
- Southampton Health Technology Assessments Centre
- UK Haemophilia Alliance
- Welsh Assembly Government